Chargement en cours...
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma
The development of targeted inhibitors, vemurafenib and dabrafenib, has led to improved clinical outcome for melanoma patients with BRAF(V600E) mutations. Although the initial response to these inhibitors can be dramatic, sometimes causing complete tumor regression, the majority of melanomas eventua...
Enregistré dans:
| Publié dans: | Oncogene |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5501768/ https://ncbi.nlm.nih.gov/pubmed/28263969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2016.526 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|